CROSSJECT (EPA:ALCJ) | WebDisclosure

PRESS RELEASE

published on 05/20/2025 at 07:30, 9 months ago

CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval
CROSSJECT plans 5 million euros capital increase, may increase to 5.8 million euros, Gemmes Venture to guarantee 75% of initial amount, Heights Capital Management supports offer

Capital Increase Crossject Gemmes Venture Heights Capital Management EUA Approval
BRIEF

published on 05/07/2025 at 07:35, 9 months 13 days ago

CROSSJECT: Progress in the EUA authorization application for ZEPIZURE®

FDA USA ZEPIZURE® BARDA CHEMPACK
BRIEF

published on 05/07/2025 at 07:35, 9 months 13 days ago

CROSSJECT : Progrès dans la demande d'autorisation EUA pour ZEPIZURE®

FDA ZEPIZURE® BARDA EUA CHEMPACK
PRESS RELEASE

published on 05/07/2025 at 07:30, 9 months 13 days ago

CROSSJECT fait un point sur les dernières avancées dans le dépôt de la demande EUA de ZEPIZURE®
CROSSJECT provides updates on the EUA filing of ZEPIZURE® for FDA Emergency Use Authorization in June 2025, supporting U.S. CHEMPACK program against chemical threats

FDA Crossject ZEPIZURE EUA Filing CHEMPACK Program
BRIEF

published on 03/27/2025 at 07:35, 10 months 24 days ago

CROSSJECT publie ses résultats financiers 2024

Résultats Financiers Partenariats Situation De Trésorerie ZEPIZURE® Dépôt Auprès De La FDA
BRIEF

published on 03/27/2025 at 07:35, 10 months 24 days ago

CROSSJECT Publishes 2024 Financial Results

Financial Results Cash Position Partnerships FDA Filing ZEPIZURE®
PRESS RELEASE

published on 03/27/2025 at 07:30, 10 months 24 days ago

CROSSJECT reports financial results for 2024
CROSSJECT reports financial results for 2024 and progress in clinical and regulatory activities, recruitment of COO, and increased cash position. Key achievements and future plans outlined

Financial Results Cash Position Clinical Activities Crossject Regulatory Development
BRIEF

published on 03/25/2025 at 07:35, 10 months 26 days ago

Strategic partnership between CROSSJECT and ETON PHARMACEUTICALS

Eton Pharmaceuticals Crossject ZENEO® Hydrocortisone Adrenal Insufficiency
BRIEF

published on 03/25/2025 at 07:35, 10 months 26 days ago

Partenariat stratégique entre CROSSJECT et ETON PHARMACEUTICALS

Eton Pharmaceuticals Crossject ZENEO® Hydrocortisone Insuffisance Surrénale
PRESS RELEASE

published on 03/25/2025 at 07:30, 10 months 26 days ago

CROSSJECT fait le point sur sa collaboration avec ETON PHARMACEUTICALS, Inc. et sur le programme ZENEO® Hydrocortisone dans le domaine de l'insuffisance surrénale
CROSSJECT renforce sa collaboration avec ETON PHARMACEUTICALS pour le programme ZENEO® Hydrocortisone dans l'insuffisance surrénale, avec des depôts de dossiers prévus à partir de S2 2026

Collaboration Eton Pharmaceuticals Crossject Insuffisance Surrénale ZENEO® Hydrocortisone

Published on 02/20/2026 at 23:15, 1 hour 14 minutes ago

DigiPower X Announces Closing of Settlement
Published on 02/20/2026 at 23:00, 1 hour 29 minutes ago

Infinico Metals Corp. Announces Effective Date for 15-for-1 Common Share Consolidation
Published on 02/20/2026 at 22:17, 2 hours 12 minutes ago

Organto Foods Completes Warrant Exercise Incentive Program
Published on 02/20/2026 at 21:40, 2 hours 49 minutes ago

IBC Advanced Alloys Announces Closing of Initial US$1,250,000 Funding by The Lind Partners
Published on 02/20/2026 at 20:15, 4 hours 14 minutes ago

Lithium South Announces Results of its Annual and Special Meeting of Securityholders

View all ACCESSWIRE

Published on 02/20/2026 at 18:36, 5 hours 53 minutes ago

EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 5 hours 58 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:23, 6 hours 6 minutes ago

POS-Transaction in Own Shares
Published on 02/20/2026 at 18:00, 6 hours 29 minutes ago

Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 6 hours 29 minutes ago

Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations

View all EQS

Published on 02/20/2026 at 19:29, 5 hours ago

SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 19:29, 5 hours ago

SFPI GROUP: bilan du contrat de liquidité S2 S025
Published on 02/20/2026 at 18:00, 6 hours 29 minutes ago

TERACT - Termination of liquidity agreement
Published on 02/20/2026 at 18:00, 6 hours 29 minutes ago

TERACT - Résiliation du contrat de liquidité
Published on 02/20/2026 at 17:35, 6 hours 54 minutes ago

CHIFFRE D'AFFAIRES 2025

View all LES ECHOS COMFI WIRE

News